Adam Cohen
Child & Adolescent Psychiatry · New York, NYNPI 1285873844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 41.6% of the total. Reporting peaked in 2024 at $911 and has fallen 57.2% since, to $390 in 2025.
Across 174 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$244
- Idorsia Pharmaceuticals US Inc$231
- Lundbeck LLC$231
- Otsuka America Pharmaceutical, Inc.$139
- Supernus Pharmaceuticals, Inc.$115
- plus $559 from 15 others
What the payments were for
- Food & beverage$2,55798%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $1,084 |
| Johnson & Johnson | 3 | $244 |
| Idorsia Pharmaceuticals US Inc | 14 | $231 |
| Lundbeck LLC | 17 | $231 |
| Otsuka America Pharmaceutical, Inc. | 8 | $139 |
| Supernus Pharmaceuticals, Inc. | 5 | $115 |
| Mentor Worldwide LLC | 1 | $112 |
| Sunovion Pharmaceuticals Inc. | 7 | $76 |
| Corium, LLC | 4 | $66 |
| Arbor Pharmaceuticals, Inc. | 5 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Tris Pharma Inc | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Alkermes, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Harmony Biosciences LLC | 1 | $15 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$145
- TECVAYLI$145
- TALVEY$145
- CARVYKTI$145
- MENTOR MemoryGel Resterilizable Gel Sizer$112
How this compares
$2,604 in reported general payments places this provider in the 85th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in New York
- Matthew LorberNew York$398K
- Jeffrey NewcornNew York$165K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Alexander KolevzonNew York$10K
- Moira RynnNew York$8K
- Jeremy Veenstra-VanderweeleNew York$7K
- Eric AlceraNew York$6K
- Philip VincentNew York$2K
- Shannon DelaneyNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.